3 results about "Platinum chemotherapy" patented technology

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise-induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and / or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention discloses a biomarker for predicting the sensitivity / prognosis of non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy drugs, and its application, belonging to the field of tumor biology technology. The biomarker is MT-ND6. MT-ND6 is an indicator of NSCLC's sensitivity to platinum-based chemotherapy, helping to avoid unnecessary treatment, reduce ineffective treatment, and minimize unnecessary chemotherapy side effects. The biomarker MT-ND6 can also serve as an independent marker distinguishing NSCLC tumor tissue from adjacent normal tissue; the expression level of MT-ND6 protein in tumor tissue is significantly higher than in normal tissue, demonstrating diagnostic value. This invention also discloses a detection reagent, a method for screening the biomarker, and a method for predicting / evaluating the sensitivity / prognosis of NSCLC treated with platinum-based chemotherapy drugs. The biomarker of this invention can be used to prepare diagnostic products for NSCLC, and has broad application prospects.